Medication Monitor

Generic Name (Trade Name—Company)
October 31, 2019


(Secuado—Noven PR)
First transdermal patch approved for treatment of adults with schizophrenia

FDA has approved asenapine transdermal system, the first transdermal patch formulation for treatment of adults with schizophrenia. In addition to offering a new delivery option, transdermal patches can also provide caretakers and health care providers with a nonintrusive, visual confirmation that a treatment is being used, said the manufacturer, Noven PR, in a news release.

The once-daily transdermal drug delivery system provides sustained concentrations during wear time (24 h) of the atypical antipsychotic drug asenapine, a well-established treatment for schizophrenia. A transdermal patch may help to mitigate some of the challenges patients face with the management of their schizophrenia.

The recommended starting dose is 3.8 mg/24 hours; the dosage may be increased to 5.7 mg/24 hours or 7.6 mg/24 hours after 1 week.

Common adverse effects of the drug include restlessness, difficulty moving, muscle stiffness, tremor, skin irritation where the patch is placed, and weight gain.

The product has a boxed warning cautioning that older adult patients with dementia-related psychosis who are treated with antipsychotic drugs are at an increased risk of death. Asenapine is not approved for treatment of patients with dementia-related psychosis.